Aging Can Be Slowed Down

Why It Matters

The discovery positions HMGB1 as a druggable target to slow systemic aging, potentially reshaping treatments for age‑related diseases and extending healthspan.

Key Takeaways

• HMGB1 identified as blood factor driving aging contagion
• Senescent cells release HMGB1, increasing systemic inflammation significantly
• Anti‑HMGB1 antibodies reduced senescence markers in mice significantly
• Treated mice showed improved muscle regeneration and physical performance
• Blocking HMGB1 restored tissue regenerative capacity in middle‑aged mice

Summary

The video discusses a July 2025 study from Korea University of Medicine that pinpointed the protein HMGB1 as a key circulating factor that accelerates aging when transferred via blood.

Building on classic parabiosis experiments—young mice rejuvenated by old blood and vice‑versa—the researchers showed that senescent cells leak HMGB1 into the bloodstream, elevating systemic inflammation and senescence markers. Administration of anti‑HMGB1 antibodies to middle‑aged mice lowered these markers, boosted muscle regeneration, and improved endurance.

Lead author Oki Jean described the mechanism as “aging as a contagion,” noting that blocking HMGB1 “restored tissue regenerative capacity.” The study reported a measurable drop in inflammatory cytokines and a 30% increase in grip strength after treatment.

If the findings translate to humans, targeting HMGB1 could become a novel anti‑aging strategy, opening avenues for therapeutics that mitigate age‑related decline and chronic inflammation.

Original Description

Scientists are studying a protein called HMGB1 that’s released by damaged or stressed cells and can trigger inflammation in nearby healthy cells, accelerating the aging process. If this research holds up, it could completely change how we think about aging and disease.